Drug Pricing Investigation: Mallinckrodt--H.P. Acthar Gel
Loading...
Serial Number
Levin Center Identifier
Document Date
2020-10-01
Report Length
50 pages
Policy Agendas Project Major Code
Policy Agendas Project Minor Code
Additional, Minority, Dissenting Views
Report Type
Found Using Methodology
Yes
Committee(s)
Subcommittee(s)
Commission(s)
Idependent Author(s)
Brief Executive Summary
The House Committee on Oversight and Reform investigated Mallinckrodt Pharmaceuticals' actions related to H.P. Acthar Gel, a drug approved in 1952 for rare infant seizure disorder and other conditions. Acthar, historically sold for less than $40 per vial, has seen an approximately 140,000% price increase over 68 years, with a typical vial now priced at $39,864. The report, based on over 140,000 pages of internal documents from 2014 to 2018, primarily examines Mallinckrodt's acquisition of Acthar and subsequent pricing practices for the medicine, shedding light on the significant price hike.